Physician profile
Iris Clark
NPI 1174887004
$5,156.52
in general payments reported to CMS, 2019-2025
57 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $709 · 2021: $1,330 · 2022: $954 · 2023: $668 · 2024: $327 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275 · Education: $96.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,275.20 |
| Education | $96.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $692.80 | 2020-2024 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $565.88 | 2019-2025 | Farxiga, Airsupra |
| Teva Pharmaceuticals USA, INC. | $292.09 | 2019-2025 | Austedo Xr, Austedo |
| Novo Nordisk INC | $241.93 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $229.22 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Amarin Pharma, INC. | $191.18 | 2019-2022 | |
| Allergan, INC. | $190.75 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $173.07 | 2019-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $171.72 | 2021-2024 | Xarelto, Spravato |
| Glaxosmithkline, LLC. | $141.06 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $139.29 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $135.41 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.40 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $126.59 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $124.74 | 2019-2023 | Rexulti, Nuedexta |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iris Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.